Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus

Cancer Imaging

Research Article

Mingan Li¹  Junyang Luo¹  Haofan Wang¹  Churen Zhou¹  Mingsheng Huang¹  Junwei Chen¹  Lisha Lai² 

[1] Department of Interventional Radiology, the Third Affiliated Hospital of Sun Yat-Sen University, 510630, Guangzhou, China;Department of Radiology, School of Medicine, Guangzhou First People’s Hospital, South China University of Technology, 510180, Guangzhou, China;

关键词: Hepatocellular carcinoma;    Main Portal vein tumour thrombus;    Transarterial chemoembolization;    Microspheres;    Survival analysis;   

DOI  :  10.1186/s40644-023-00581-8

 received in 2022-11-24, accepted in 2023-06-01,  发布年份 2023

来源: Springer

【 摘 要 】

ObjectivesTo compare the efficacy, overall survival (OS) and safety of drug-eluting beads-TACE (DEB-TACE) and C-TACE as initial treatment in advanced hepatocellular carcinoma (HCC) patients with main portal vein tumor thrombus (mPVTT).MethodsThe medical records of consecutive advanced HCC patients with mPVTT who underwent initial DEB-TACE or C-TACE from September 2015 to October 2021 were retrospectively evaluated. Treatment crossover was allowed in this retrospective research. The adverse events, disease control rate (DCR), time to tumor progression (TTP) and OS of patients who underwent DEB-TACE were compared with those of patients who underwent C-TACE.ResultsEighty-three patients were included: 42 patients in DEB-TACE group and 41 patients in C-TACE group. DEB-TACE could be safely performed in HCC patients with mPVTT, and they gained a better DCR than those submitted to the C-TACE (76.2% vs. 53.7%, P = 0.031), which might have resulted in longer TTP (median TTP: 9.0 months vs. 3.0 months, P < 0.001). Furthermore, DEB-TACE showed significant OS benefits compared with C-TACE (median OS: 12.0 months vs. 5.0 months, P < 0.001). DEB-TACE, absence of arterioportal shunts (APS), leisons with capsular non-infiltration were found to be independent prognostic factors for better OS. Furthermore, subgroup analysis proved that patients with good DCR gained longer OS in DEB-TACE group.ConclusionsDEB-TACE could be safely performed and improve the DCR of HCC patients with mPVTT, which resulting in longer TTP and OS, compared with C-TACE.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 10

Fig. 1

Fig. 6

Fig. 2

Fig. 1